Novartis has contributed $75 million towards a Series C financing for CAR-T company Poseida, which totaled $142 million from current and new investors.
https://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.png00clickgianthttps://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.pngclickgiant2019-04-22 17:36:082019-05-20 18:06:14Novartis remains in BCMA CAR-T space through Poseida investment after discontinuing in-house program
